Home > Publications > MGHI papers
MGHI papers
Metronomics: intrinsic anakoinosis modulator ?
As part of a "research topic" on anakoinosis, opened for submission in Fontiers in Pharmacology, Nicolas André, Manon Carré and Eddy Pasquier from the Department of Pediatric Hematology-Oncology, Assistance Publique Hôpitaux de Marseille, France, the Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm UMR1068, CNRS UMR7258, Aix Marseille[...]
Metronomics: towards personalized chemotherapy?
Our recent comissioned review written by Nicolas ANDRE, Manon CARRE and Eddy PASQUIER from the Service d’Hématologie & Oncologie Pédiatrique, AP-HM, the INSERM UMR 911, Centre de Recherche en Oncologie Biologique et Oncopharmacologie, Aix-Marseille University France and the Children’s Cancer Institute Australia, Lowy Cancer Research Centre,[...]
Modeling the Impact of Anticancer Agents on Metastatic Spreading
A collaboration between MGHI, the CMI-LATP and the Laboratoire de Toxicocinétique et Pharmacocinétique both from Marseille has lead to a publication entitled : Modeling the Impact of Anticancer Agents on Metastatic Spreading S. Benzekry, N. André, A. Benabdallah, J. Ciccolini, C. Faivre, F. Hubert and D. Barbolosi published in Mathematical Modelling[...]
Moving forward with metronomic scheduling of anti-cancer treatment: Meeting report of the 2nd international workshop on metronomic and antiangiogenic chemotherapy in paediatric oncology
Metronomic chemotherapy, which is defined by the frequent, repetitive administration of chemotherapeutic drugs at relatively low doses, and without prolonged drug-free break, is an emerging strategy to fight cancer. Initially thought to act by targeting tumour angiogenesis, additional mechanisms have been recently unveiled and metronomic[...]
Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic Meeting May 2016, Mumbai
The report from the last metronomic meeting that took place in Mumbai in May 2016 and organized by Pr Banavali has just been published in Ecancermedical Sciences. Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai
ABSTRACT
The 5th Biennial[...]
Paediatric metronomic four-drug metronomic regimen has anti-tumour activity in pediatric low-grade glioma; the results of a phase II clinical trial.
The SFCE (French Society for children with Cancer) in collaboration with MGHI has just published the results of the metro-SFCE01 trial in Frontiers in Pharmacology. The article entitled "Paediatric metronomic four-drug metronomic regimen has anti-tumour activity in pediatric low-grade glioma; the results of a phase II clinical trial " authored by[...]
Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX)
We are very glad to share the recent article reporting the Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX) by Pierre Leblond ,Emmanuelle Tresch-Bruneel,Alicia Probst ,Nadège Néant,Caroline Solas ,Arthur Sterin,Thomas Boulanger,Isabelle Aerts,Cécile[...]
PK/PD-based mathematical modeling identifies an optimal protocol for metronomic chemotherapy
We are very proud to share our new paper about PK-PD modelling and metronomic chemotherapy. This article entitled : Pharmacokinetics and pharmacodynamics-based mathematical modeling identifies an optimal protocol for metronomic chemotherapy by Joseph Ciccolini, Dominique Barbolosi, Christophe Meille, Aurelie Lombard, Cindy Serdjebi, Sarah Giacometti,[...]
Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02.
We are very please to announce that our preliminary experience with a combination of metronomic chemotherapy and the introduction of target therapies with valproic acid , as an repositioned HDAC inhibitor as just been published by the indian journal of cancer. The study was lead by Dr Fousseiny Traore in the pediatric oncology unit of Bamako in Mali.[...]
Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment
To propose new cheap and non toxic treatments to all, we recently worked on propranolol. We show here for the first time that propranolol can an potentiate the anti-angiogenic effects and anti-tumor efficacy of chemotherapy.
You can read the full paper here in Oncotarget an open access journal
